Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Special Survey on Parkinson's Disease Patients Treated Long-term Use of Pramipexole

10 juni 2014 bijgewerkt door: Boehringer Ingelheim

Pramipexole Special Survey on Long-Term Use

The survey is conducted to collect safety and effectiveness information on the use of Pramipexole for long time of period in daily clinical settings in Japan.

Studie Overzicht

Toestand

Voltooid

Conditie

Studietype

Observationeel

Inschrijving (Werkelijk)

1645

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

  • Japan
      • Agano, Japan
        • Boehringer Ingelheim Investigational Site
      • Aizuwakamatsu, Japan
        • Boehringer Ingelheim Investigational Site
      • Akashi, Japan
        • Boehringer Ingelheim Investigational Site
      • Akita, Japan
        • Boehringer Ingelheim Investigational Site
      • Asahikawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Asakura, Japan
        • Boehringer Ingelheim Investigational Site
      • Ayagawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Azumino, Japan
        • Boehringer Ingelheim Investigational Site
      • Bando, Japan
        • Boehringer Ingelheim Investigational Site
      • Beppu, Japan
        • Boehringer Ingelheim Investigational Site
      • Bihoro, Japan
        • Boehringer Ingelheim Investigational Site
      • Chiba, Japan
        • Boehringer Ingelheim Investigational Site
      • Chikusei, Japan
        • Boehringer Ingelheim Investigational Site
      • Chuo, Japan
        • Boehringer Ingelheim Investigational Site
      • Date, Japan
        • Boehringer Ingelheim Investigational Site
      • Ebetsu, Japan
        • Boehringer Ingelheim Investigational Site
      • Ebina, Japan
        • Boehringer Ingelheim Investigational Site
      • Eiheiji, Japan
        • Boehringer Ingelheim Investigational Site
      • Fuchu, Japan
        • Boehringer Ingelheim Investigational Site
      • Fuji, Japan
        • Boehringer Ingelheim Investigational Site
      • Fujieda, Japan
        • Boehringer Ingelheim Investigational Site
      • Fujinomiya, Japan
        • Boehringer Ingelheim Investigational Site
      • Fujioka, Japan
        • Boehringer Ingelheim Investigational Site
      • Fujisawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Fujiyoshida, Japan
        • Boehringer Ingelheim Investigational Site
      • Fukaya, Japan
        • Boehringer Ingelheim Investigational Site
      • Fukui, Japan
        • Boehringer Ingelheim Investigational Site
      • Fukuoka, Japan
        • Boehringer Ingelheim Investigational Site
      • Fukushima, Japan
        • Boehringer Ingelheim Investigational Site
      • Fukuyama, Japan
        • Boehringer Ingelheim Investigational Site
      • Geisei, Japan
        • Boehringer Ingelheim Investigational Site
      • Gifu, Japan
        • Boehringer Ingelheim Investigational Site
      • Ginowan, Japan
        • Boehringer Ingelheim Investigational Site
      • Hachinohe, Japan
        • Boehringer Ingelheim Investigational Site
      • Hadano, Japan
        • Boehringer Ingelheim Investigational Site
      • Haebaru, Japan
        • Boehringer Ingelheim Investigational Site
      • Hagahama, Japan
        • Boehringer Ingelheim Investigational Site
      • Hakodate, Japan
        • Boehringer Ingelheim Investigational Site
      • Hamada, Japan
        • Boehringer Ingelheim Investigational Site
      • Hamamatsu, Japan
        • Boehringer Ingelheim Investigational Site
      • Hayashima, Japan
        • Boehringer Ingelheim Investigational Site
      • Higashimurayama, Japan
        • Boehringer Ingelheim Investigational Site
      • Higashiosaka, Japan
        • Boehringer Ingelheim Investigational Site
      • Higashiyamato, Japan
        • Boehringer Ingelheim Investigational Site
      • Himeji, Japan
        • Boehringer Ingelheim Investigational Site
      • Hiratsuka, Japan
        • Boehringer Ingelheim Investigational Site
      • Hirokawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Hirosaki, Japan
        • Boehringer Ingelheim Investigational Site
      • Hiroshima, Japan
        • Boehringer Ingelheim Investigational Site
      • Hita, Japan
        • Boehringer Ingelheim Investigational Site
      • Hofu, Japan
        • Boehringer Ingelheim Investigational Site
      • Ibaragi, Japan
        • Boehringer Ingelheim Investigational Site
      • Ichikikushikino, Japan
        • Boehringer Ingelheim Investigational Site
      • Ichinomiya, Japan
        • Boehringer Ingelheim Investigational Site
      • Ichinoseki, Japan
        • Boehringer Ingelheim Investigational Site
      • Iizuka, Japan
        • Boehringer Ingelheim Investigational Site
      • Ikeda, Japan
        • Boehringer Ingelheim Investigational Site
      • Ikoma, Japan
        • Boehringer Ingelheim Investigational Site
      • Ina, Japan
        • Boehringer Ingelheim Investigational Site
      • Inazawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Inba, Japan
        • Boehringer Ingelheim Investigational Site
      • Inuyama, Japan
        • Boehringer Ingelheim Investigational Site
      • Isezaki, Japan
        • Boehringer Ingelheim Investigational Site
      • Itoigawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Iwaki, Japan
        • Boehringer Ingelheim Investigational Site
      • Iwata, Japan
        • Boehringer Ingelheim Investigational Site
      • Joetsu, Japan
        • Boehringer Ingelheim Investigational Site
      • Kagoshima, Japan
        • Boehringer Ingelheim Investigational Site
      • Kahoku, Japan
        • Boehringer Ingelheim Investigational Site
      • Kajiki, Japan
        • Boehringer Ingelheim Investigational Site
      • Kakegawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Kakogawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Kamisu, Japan
        • Boehringer Ingelheim Investigational Site
      • Kamogawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Kanazawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Kannonji, Japan
        • Boehringer Ingelheim Investigational Site
      • Karatsu, Japan
        • Boehringer Ingelheim Investigational Site
      • Kashima, Japan
        • Boehringer Ingelheim Investigational Site
      • Kashiwa, Japan
        • Boehringer Ingelheim Investigational Site
      • Kashiwazaki, Japan
        • Boehringer Ingelheim Investigational Site
      • Kasukabe, Japan
        • Boehringer Ingelheim Investigational Site
      • Kato, Japan
        • Boehringer Ingelheim Investigational Site
      • Kawagoe, Japan
        • Boehringer Ingelheim Investigational Site
      • Kawasaki, Japan
        • Boehringer Ingelheim Investigational Site
      • Kawatana, Japan
        • Boehringer Ingelheim Investigational Site
      • Kikugawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Kirishima, Japan
        • Boehringer Ingelheim Investigational Site
      • Kitakyushu, Japan
        • Boehringer Ingelheim Investigational Site
      • Kiyose, Japan
        • Boehringer Ingelheim Investigational Site
      • Kiyotake, Japan
        • Boehringer Ingelheim Investigational Site
      • Kizugawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Kobayashi, Japan
        • Boehringer Ingelheim Investigational Site
      • Kobe, Japan
        • Boehringer Ingelheim Investigational Site
      • Kochi, Japan
        • Boehringer Ingelheim Investigational Site
      • Kodaira, Japan
        • Boehringer Ingelheim Investigational Site
      • Kofu, Japan
        • Boehringer Ingelheim Investigational Site
      • Koga, Japan
        • Boehringer Ingelheim Investigational Site
      • Kokubunji, Japan
        • Boehringer Ingelheim Investigational Site
      • Komae, Japan
        • Boehringer Ingelheim Investigational Site
      • Komatsu, Japan
        • Boehringer Ingelheim Investigational Site
      • Komoro, Japan
        • Boehringer Ingelheim Investigational Site
      • Koriyama, Japan
        • Boehringer Ingelheim Investigational Site
      • Koshi, Japan
        • Boehringer Ingelheim Investigational Site
      • Koshigawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Kumamoto, Japan
        • Boehringer Ingelheim Investigational Site
      • Kurashiki, Japan
        • Boehringer Ingelheim Investigational Site
      • Kurayoshi, Japan
        • Boehringer Ingelheim Investigational Site
      • Kure, Japan
        • Boehringer Ingelheim Investigational Site
      • Kurume, Japan
        • Boehringer Ingelheim Investigational Site
      • Kushiro, Japan
        • Boehringer Ingelheim Investigational Site
      • Kutchan, Japan
        • Boehringer Ingelheim Investigational Site
      • Kuwana, Japan
        • Boehringer Ingelheim Investigational Site
      • Kyonan, Japan
        • Boehringer Ingelheim Investigational Site
      • Kyoto, Japan
        • Boehringer Ingelheim Investigational Site
      • Maebaru, Japan
        • Boehringer Ingelheim Investigational Site
      • Maebashi, Japan
        • Boehringer Ingelheim Investigational Site
      • Maibara, Japan
        • Boehringer Ingelheim Investigational Site
      • Maizuru, Japan
        • Boehringer Ingelheim Investigational Site
      • Marugame, Japan
        • Boehringer Ingelheim Investigational Site
      • Matsuda, Japan
        • Boehringer Ingelheim Investigational Site
      • Matsudo, Japan
        • Boehringer Ingelheim Investigational Site
      • Matsue, Japan
        • Boehringer Ingelheim Investigational Site
      • Matsumoto, Japan
        • Boehringer Ingelheim Investigational Site
      • Matsuyama, Japan
        • Boehringer Ingelheim Investigational Site
      • Mibu, Japan
        • Boehringer Ingelheim Investigational Site
      • Mihara, Japan
        • Boehringer Ingelheim Investigational Site
      • Miki, Japan
        • Boehringer Ingelheim Investigational Site
      • Minakami, Japan
        • Boehringer Ingelheim Investigational Site
      • Minamata, Japan
        • Boehringer Ingelheim Investigational Site
      • Minobu, Japan
        • Boehringer Ingelheim Investigational Site
      • Misashino, Japan
        • Boehringer Ingelheim Investigational Site
      • Mito, Japan
        • Boehringer Ingelheim Investigational Site
      • Miyaki, Japan
        • Boehringer Ingelheim Investigational Site
      • Miyakonojo, Japan
        • Boehringer Ingelheim Investigational Site
      • Miyazaki, Japan
        • Boehringer Ingelheim Investigational Site
      • Mooka, Japan
        • Boehringer Ingelheim Investigational Site
      • Moriguchi, Japan
        • Boehringer Ingelheim Investigational Site
      • Morioka, Japan
        • Boehringer Ingelheim Investigational Site
      • Moriya, Japan
        • Boehringer Ingelheim Investigational Site
      • Moriyama, Japan
        • Boehringer Ingelheim Investigational Site
      • Muroran, Japan
        • Boehringer Ingelheim Investigational Site
      • Nagakute, Japan
        • Boehringer Ingelheim Investigational Site
      • Nagaoka, Japan
        • Boehringer Ingelheim Investigational Site
      • Nagaokakyo, Japan
        • Boehringer Ingelheim Investigational Site
      • Nagasaki, Japan
        • Boehringer Ingelheim Investigational Site
      • Nagoya, Japan
        • Boehringer Ingelheim Investigational Site
      • Nangoku, Japan
        • Boehringer Ingelheim Investigational Site
      • Nara, Japan
        • Boehringer Ingelheim Investigational Site
      • Narita, Japan
        • Boehringer Ingelheim Investigational Site
      • Naruto, Japan
        • Boehringer Ingelheim Investigational Site
      • Nichinan, Japan
        • Boehringer Ingelheim Investigational Site
      • Niigata, Japan
        • Boehringer Ingelheim Investigational Site
      • Niihama, Japan
        • Boehringer Ingelheim Investigational Site
      • Nikko, Japan
        • Boehringer Ingelheim Investigational Site
      • Nishigo, Japan
        • Boehringer Ingelheim Investigational Site
      • Nishihara, Japan
        • Boehringer Ingelheim Investigational Site
      • Nishinomiya, Japan
        • Boehringer Ingelheim Investigational Site
      • Nishio, Japan
        • Boehringer Ingelheim Investigational Site
      • Nishitokyo, Japan
        • Boehringer Ingelheim Investigational Site
      • Nobeoka, Japan
        • Boehringer Ingelheim Investigational Site
      • Noboribetsu, Japan
        • Boehringer Ingelheim Investigational Site
      • Numazu, Japan
        • Boehringer Ingelheim Investigational Site
      • Obama, Japan
        • Boehringer Ingelheim Investigational Site
      • Obihiro, Japan
        • Boehringer Ingelheim Investigational Site
      • Odate, Japan
        • Boehringer Ingelheim Investigational Site
      • Odawara, Japan
        • Boehringer Ingelheim Investigational Site
      • Ofunato, Japan
        • Boehringer Ingelheim Investigational Site
      • Ogaki, Japan
        • Boehringer Ingelheim Investigational Site
      • Ohzu, Japan
        • Boehringer Ingelheim Investigational Site
      • Oiso, Japan
        • Boehringer Ingelheim Investigational Site
      • Oita, Japan
        • Boehringer Ingelheim Investigational Site
      • Ojiya, Japan
        • Boehringer Ingelheim Investigational Site
      • Okawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Okayama, Japan
        • Boehringer Ingelheim Investigational Site
      • Omaezaki, Japan
        • Boehringer Ingelheim Investigational Site
      • Omura, Japan
        • Boehringer Ingelheim Investigational Site
      • Omuta, Japan
        • Boehringer Ingelheim Investigational Site
      • Onga, Japan
        • Boehringer Ingelheim Investigational Site
      • Onojo, Japan
        • Boehringer Ingelheim Investigational Site
      • Onomichi, Japan
        • Boehringer Ingelheim Investigational Site
      • Osaka, Japan
        • Boehringer Ingelheim Investigational Site
      • Otsu, Japan
        • Boehringer Ingelheim Investigational Site
      • Ozu, Japan
        • Boehringer Ingelheim Investigational Site
      • Sado, Japan
        • Boehringer Ingelheim Investigational Site
      • Saga, Japan
        • Boehringer Ingelheim Investigational Site
      • Sagamihara, Japan
        • Boehringer Ingelheim Investigational Site
      • Saitama, Japan
        • Boehringer Ingelheim Investigational Site
      • Sakai, Japan
        • Boehringer Ingelheim Investigational Site
      • Sakaide, Japan
        • Boehringer Ingelheim Investigational Site
      • Sakata, Japan
        • Boehringer Ingelheim Investigational Site
      • Saku, Japan
        • Boehringer Ingelheim Investigational Site
      • Sanjo, Japan
        • Boehringer Ingelheim Investigational Site
      • Sano, Japan
        • Boehringer Ingelheim Investigational Site
      • Sanyoonoda, Japan
        • Boehringer Ingelheim Investigational Site
      • Sapporo, Japan
        • Boehringer Ingelheim Investigational Site
      • Sasebo, Japan
        • Boehringer Ingelheim Investigational Site
      • Seijo, Japan
        • Boehringer Ingelheim Investigational Site
      • Sendai, Japan
        • Boehringer Ingelheim Investigational Site
      • Shimabara, Japan
        • Boehringer Ingelheim Investigational Site
      • Shimonoseki, Japan
        • Boehringer Ingelheim Investigational Site
      • Shimotsuke, Japan
        • Boehringer Ingelheim Investigational Site
      • Shingu, Japan
        • Boehringer Ingelheim Investigational Site
      • Shinshiro, Japan
        • Boehringer Ingelheim Investigational Site
      • Shizuoka, Japan
        • Boehringer Ingelheim Investigational Site
      • Shunan, Japan
        • Boehringer Ingelheim Investigational Site
      • Soo, Japan
        • Boehringer Ingelheim Investigational Site
      • Suita, Japan
        • Boehringer Ingelheim Investigational Site
      • Tajimi, Japan
        • Boehringer Ingelheim Investigational Site
      • Takamatsu, Japan
        • Boehringer Ingelheim Investigational Site
      • Takanabe, Japan
        • Boehringer Ingelheim Investigational Site
      • Takaoka, Japan
        • Boehringer Ingelheim Investigational Site
      • Takasago, Japan
        • Boehringer Ingelheim Investigational Site
      • Takasaki, Japan
        • Boehringer Ingelheim Investigational Site
      • Takatsuki, Japan
        • Boehringer Ingelheim Investigational Site
      • Takehara, Japan
        • Boehringer Ingelheim Investigational Site
      • Toda, Japan
        • Boehringer Ingelheim Investigational Site
      • Togitsu, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokoname, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokushima, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Adachi-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Bunkyo-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Chiyoda-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Edogawa-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Itabashi-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Katsushika-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Kita-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Meguro-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Minayo-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Nakano-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Nerima-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Ota-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Setagaya-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Shinagawa-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Shinjuku-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Suginami-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Toshima-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tomakomai, Japan
        • Boehringer Ingelheim Investigational Site
      • Tomiai, Japan
        • Boehringer Ingelheim Investigational Site
      • Tondabayashi, Japan
        • Boehringer Ingelheim Investigational Site
      • Toon, Japan
        • Boehringer Ingelheim Investigational Site
      • Toride, Japan
        • Boehringer Ingelheim Investigational Site
      • Toyama, Japan
        • Boehringer Ingelheim Investigational Site
      • Toyoake, Japan
        • Boehringer Ingelheim Investigational Site
      • Toyokawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Toyonaka, Japan
        • Boehringer Ingelheim Investigational Site
      • Toyooka, Japan
        • Boehringer Ingelheim Investigational Site
      • Tsu, Japan
        • Boehringer Ingelheim Investigational Site
      • Tsubata, Japan
        • Boehringer Ingelheim Investigational Site
      • Tsuchiura, Japan
        • Boehringer Ingelheim Investigational Site
      • Tsukuba, Japan
        • Boehringer Ingelheim Investigational Site
      • Tsuruoka, Japan
        • Boehringer Ingelheim Investigational Site
      • Uchinada, Japan
        • Boehringer Ingelheim Investigational Site
      • Ueda, Japan
        • Boehringer Ingelheim Investigational Site
      • Uji, Japan
        • Boehringer Ingelheim Investigational Site
      • Ujo, Japan
        • Boehringer Ingelheim Investigational Site
      • Urayasu, Japan
        • Boehringer Ingelheim Investigational Site
      • Uruma, Japan
        • Boehringer Ingelheim Investigational Site
      • Utsunomiya, Japan
        • Boehringer Ingelheim Investigational Site
      • Wakayama, Japan
        • Boehringer Ingelheim Investigational Site
      • Yamagata, Japan
        • Boehringer Ingelheim Investigational Site
      • Yamaguchi, Japan
        • Boehringer Ingelheim Investigational Site
      • Yamamoto, Japan
        • Boehringer Ingelheim Investigational Site
      • Yanai, Japan
        • Boehringer Ingelheim Investigational Site
      • Yao, Japan
        • Boehringer Ingelheim Investigational Site
      • Yashiro, Japan
        • Boehringer Ingelheim Investigational Site
      • Yazu, Japan
        • Boehringer Ingelheim Investigational Site
      • Yokkaichi, Japan
        • Boehringer Ingelheim Investigational Site
      • Yokohama, Japan
        • Boehringer Ingelheim Investigational Site
      • Yokote, Japan
        • Boehringer Ingelheim Investigational Site
      • Yoro, Japan
        • Boehringer Ingelheim Investigational Site
      • Yoshinogawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Yufu, Japan
        • Boehringer Ingelheim Investigational Site
      • Zama, Japan
        • Boehringer Ingelheim Investigational Site

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Kind
  • Volwassen
  • Oudere volwassene

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Bemonsteringsmethode

Niet-waarschijnlijkheidssteekproef

Studie Bevolking

Parkinson's disease patients in daily clinical settings

Beschrijving

Inclusion Criteria:

Patients with Parkinson's disease

Exclusion Criteria:

Patients should have been treated according to the Japanese insert slip

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Proportion of Adverse Events, Adverse Drug Reactions, Serious Adverse Events
Tijdsspanne: during 18 months
The aim of this Post Marketing Surveillance (PMS) was to obtain long-term safety data with treatment of pramipexole in Parkinson's disease (PD) patients. Therefore these items were considered as a safety evaluation.
during 18 months

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Clinical Global Impression of Improvement
Tijdsspanne: 18 months
Investigators evaluation of the PD symptoms on a rating scale of 5 categories (very much improved, much improved, minimally improved, no effect, and unassessable).
18 months
Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Total Score
Tijdsspanne: Baseline and at 18 months (or at the time of discontinuation)
Motor examination is assessed by 27 questionnaire items in UPDRS Part III section. Each item is scored from 0 (best) to 4 (worst), and the total score of UPDRS Part III is from 0 (best) to 108 (worst). A decrease in the score means improvement.
Baseline and at 18 months (or at the time of discontinuation)
Change From Baseline in Modified Hoehn & Yahr Rating Scale
Tijdsspanne: Baseline and at 18 months (or at the time of discontinuation)
A severity of PD symptom are assessed by Modified Hoehn & Yahr rating scale. This scale consist of 10 levels including additional evaluation levels defined in Japan. Ten levels are described by 0 (best), 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5 (worst).
Baseline and at 18 months (or at the time of discontinuation)

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Boehringer Ingelheim

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Nuttige links

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start

1 februari 2004

Primaire voltooiing (Werkelijk)

1 maart 2009

Studieregistratiedata

Eerst ingediend

31 januari 2008

Eerst ingediend dat voldeed aan de QC-criteria

13 februari 2008

Eerst geplaatst (Schatting)

14 februari 2008

Updates van studierecords

Laatste update geplaatst (Schatting)

11 juli 2014

Laatste update ingediend die voldeed aan QC-criteria

10 juni 2014

Laatst geverifieerd

1 juni 2014

Meer informatie

Termen gerelateerd aan deze studie

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • 248.547

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren